NanoParma BioMedical Ltd.
Update：2026/09/15
Industries
Main Industry
Health Care
Main Product/Service
High-accuracy early disease detection platforms, home-use testing devices, and professional medical automated testing devices; "Nano Shield" (NanoParma BioMedical Ltd.) suspended particles, when paired with an ultrasonic atomizer (spray), can remain suspended in the air for a long duration of up to 2 hours. They bind with the receptor binding domain (RBD) of the spike protein on the SARS-CoV-2 virus in aerosols, causing the virus to settle. Within 30 minutes, they can bind 40% to 60% of the SARS-CoV-2 virus in the air, reducing the risk of virus transmission and achieving an active, long-lasting defensive effect.
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2021
Unified Business No.
90704445
Status
Closed
Number of Employees
0
Total Paid-in
Capital
0 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Post-COVID-19, telemedicine utilization rates have increased by 35 to 63 times. By utilizing the home-use testing device NanoPAL™ and the SeraParma™ high-accuracy rapid testing platform to detect disease-related biomarkers that cause symptoms such as chest pain and difficulty breathing, and pairing this with telemedicine services to assist physicians in making subsequent medical decisions, unnecessary emergency department visits can be reduced to alleviate the burden of healthcare costs (emergency department costs in the United States are 12 times those of regular outpatient visits, with over $32 billion in emergency medical expenses generated annually).
(The content above was translated by AI.)
(The content above was translated by AI.)
